Sana Biotechnology

### Executive Summary Sana Biotechnology raised $943.4M in a Regulation D private placement, the first sale occurring on 2025-10-12. The offering is in synthetic biology and intracellular mRNA delivery, with Lockheed Martin Ventures and Bessemer Venture Partners listed as related persons. ### Investor Edge Monitor for subsequent Form D/A amendments which could indicate additional capital or changed terms, and watch for any public filings (e.g., S-1) suggesting an eventual IPO. ### Sector capital positioning This massive raise signals strong capital flow into synthetic biology and mRNA delivery, indicating sustained investor appetite for cutting-edge biotech platforms. ### Convergence Signals No clear public signals (patents, contracts, legislation) are evident from the filing. The presence of Lockheed Martin Ventures may hint at defense or aerospace applications, but this is speculative. ### Key Takeaways - Regulation D private placement of $943.4M, first sale 2025-10-12. - Investors include Lockheed Martin Ventures and Bessemer Venture Partners. - Large raise for private synthetic biology and mRNA delivery company. ### Risk Indicators & Flags No red flags observed. The filing is an initial Form D (not D/A), and the amount is large but not unprecedented for high-profile biotech. No regulatory concerns evident. ### Verification & References Verify filing via SEC EDGAR at accession 0001702600-24-20391. Confirm first sale date and capital amount. Check for any later D/A filings under company name.